Literature DB >> 25523197

Mouse models for therapeutic vaccination against hepatitis B virus.

Claudia Dembek1, Ulrike Protzer.   

Abstract

A mouse model for persistent HBV infection is essential for the development of a therapeutic vaccine against HBV. Because HBV cannot infect mouse hepatocytes, even if the HBV receptor is introduced, surrogate models are used. A suitable model needs to establish persistent HBV replication and must allow the establishment of HBV-specific adaptive cellular and humoral immune responses. Therefore, an immunocompetent mouse model is needed in which one can break HBV-specific tolerance and ideally eliminate the HBV transcription template. The most widely used model for chronic HBV infection is the HBV transgenic mouse. Although HBV replicates from an integrated transgene, HBV-specific immune tolerance can be broken upon adequate immune stimulation because antigen expression only starts shortly before birth. Alternative mouse models of chronic HBV infection are generated by introducing HBV genomes either using viral vectors or using hydrodynamic injection. In these alternative models, the HBV transcription template is introduced into a proportion of hepatocytes and stays extra-chromosomal. It thus mimics the natural HBV transcription template, the HBV cccDNA in humans. Unlike an HBV transgene, however, it can be cleared upon appropriate treatment or immune stimulation. Human hepatocyte chimeric mice in which murine hepatocytes are widely replaced by human hepatocytes represent another important mouse model for persistent HBV infection. These mice are susceptible for HBV infection, but need to be severely immune deficient to accept human hepatocytes. In conclusion, a variety of mouse models for persistent HBV infection are available suitable for preclinical efficacy evaluations of therapeutic vaccination strategies against HBV.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25523197     DOI: 10.1007/s00430-014-0378-6

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  42 in total

1.  Actively acquired tolerance of foreign cells.

Authors:  R E BILLINGHAM; L BRENT; P B MEDAWAR
Journal:  Nature       Date:  1953-10-03       Impact factor: 49.962

2.  A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks.

Authors:  J Summers; J M Smolec; R Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1978-09       Impact factor: 11.205

Review 3.  Animal model for study of human hepatitis viruses.

Authors:  Kazuaki Chayama; C Nelson Hayes; Nobuhiko Hiraga; Hiromi Abe; Masataka Tsuge; Michio Imamura
Journal:  J Gastroenterol Hepatol       Date:  2011-01       Impact factor: 4.029

4.  Generation of a humanized mouse model with both human immune system and liver cells to model hepatitis C virus infection and liver immunopathogenesis.

Authors:  Moses T Bility; Liguo Zhang; Michael L Washburn; T Anthony Curtis; Grigoriy I Kovalev; Lishan Su
Journal:  Nat Protoc       Date:  2012-08-09       Impact factor: 13.491

5.  Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection.

Authors:  Priscilla L Yang; Alana Althage; Josan Chung; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-08       Impact factor: 11.205

6.  Repopulation of adult and neonatal mice with human hepatocytes: a chimeric animal model.

Authors:  Karl-Dimiter Bissig; Tam T Le; Niels-Bjarne Woods; Inder M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-11       Impact factor: 11.205

7.  Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection.

Authors:  Wendy K Foster; Darren S Miller; Patricia L Marion; Richard J Colonno; Ieva Kotlarski; Allison R Jilbert
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

8.  Adeno-associated virus-mediated gene transfer leads to persistent hepatitis B virus replication in mice expressing HLA-A2 and HLA-DR1 molecules.

Authors:  Sarah Dion; Maryline Bourgine; Ophélie Godon; Florence Levillayer; Marie-Louise Michel
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

9.  Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages.

Authors:  Moses T Bility; Liang Cheng; Zheng Zhang; Yan Luan; Feng Li; Liqun Chi; Liguo Zhang; Zhengkun Tu; Yanhang Gao; Yangxin Fu; Junqi Niu; Fusheng Wang; Lishan Su
Journal:  PLoS Pathog       Date:  2014-03-20       Impact factor: 6.823

10.  Combination of DNA prime--adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model.

Authors:  Anna D Kosinska; Ejuan Zhang; Lena Johrden; Jia Liu; Pia L Seiz; Xiaoyong Zhang; Zhiyong Ma; Thekla Kemper; Melanie Fiedler; Dieter Glebe; Oliver Wildner; Ulf Dittmer; Mengji Lu; Michael Roggendorf
Journal:  PLoS Pathog       Date:  2013-06-13       Impact factor: 6.823

View more
  9 in total

1.  MAVS-dependent host species range and pathogenicity of human hepatitis A virus.

Authors:  Asuka Hirai-Yuki; Lucinda Hensley; David R McGivern; Olga González-López; Anshuman Das; Hui Feng; Lu Sun; Justin E Wilson; Fengyu Hu; Zongdi Feng; William Lovell; Ichiro Misumi; Jenny P-Y Ting; Stephanie Montgomery; John Cullen; Jason K Whitmire; Stanley M Lemon
Journal:  Science       Date:  2016-09-15       Impact factor: 47.728

2.  Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model.

Authors:  Danqing Hu; Hongwu Wang; Hai Wang; Yaqi Wang; Xiaoyang Wan; Weiming Yan; Xiaoping Luo; Qin Ning
Journal:  Hepatol Int       Date:  2018-07-05       Impact factor: 6.047

Review 3.  Research progress of therapeutic vaccines for treating chronic hepatitis B.

Authors:  Jianqiang Li; Mengru Bao; Jun Ge; Sulin Ren; Tong Zhou; Fengchun Qi; Xiuying Pu; Jia Dou
Journal:  Hum Vaccin Immunother       Date:  2017-01-24       Impact factor: 3.452

4.  Fibronectin EDA and CpG synergize to enhance antigen-specific Th1 and cytotoxic responses.

Authors:  Ziad Julier; Alexandre de Titta; Alizée J Grimm; Eleonora Simeoni; Melody A Swartz; Jeffrey A Hubbell
Journal:  Vaccine       Date:  2016-03-24       Impact factor: 3.641

5.  Transcriptome Analysis and Comparison of Marmota monax and Marmota himalayana.

Authors:  Yanan Liu; Baoju Wang; Lu Wang; Vikash Vikash; Qin Wang; Michael Roggendorf; Mengji Lu; Dongliang Yang; Jia Liu
Journal:  PLoS One       Date:  2016-11-02       Impact factor: 3.240

6.  Enrichment of Ly6Chi monocytes by multiple GM-CSF injections with HBV vaccine contributes to viral clearance in a HBV mouse model.

Authors:  Weidong Zhao; Xian Zhou; Gan Zhao; Qing Lin; Xianzheng Wang; Xueping Yu; Bin Wang
Journal:  Hum Vaccin Immunother       Date:  2017-07-12       Impact factor: 3.452

7.  T cell--associated immunoregulation and antiviral effect of oxymatrine in hydrodynamic injection HBV mouse model.

Authors:  Xiuxiu Sang; Ruilin Wang; Yanzhong Han; Cong'en Zhang; Honghui Shen; Zhirui Yang; Yin Xiong; Huimin Liu; Shijing Liu; Ruisheng Li; Ruichuang Yang; Jiabo Wang; Xuejun Wang; Zhaofang Bai; Xiaohe Xiao
Journal:  Acta Pharm Sin B       Date:  2017-05-02       Impact factor: 11.413

8.  A hepatitis B virus transgenic mouse model with a conditional, recombinant, episomal genome.

Authors:  Robert L Kruse; Mercedes Barzi; Xavier Legras; Francis P Pankowicz; Nika Furey; Lan Liao; Janming Xu; Beatrice Bissig-Choisat; Betty L Slagle; Karl-Dimiter Bissig
Journal:  JHEP Rep       Date:  2021-02-06

9.  Protocol for chronic hepatitis B virus infection mouse model development by patient-derived orthotopic xenografts.

Authors:  Aleksey M Nagornykh; Marina A Tyumentseva; Aleksandr I Tyumentsev; Vasiliy G Akimkin
Journal:  PLoS One       Date:  2022-02-23       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.